131 related articles for article (PubMed ID: 11323371)
41. Anti-ischaemic efficacy of L-propionylcarnitine--a promising novel metabolic approach to ischaemia?
Bartels GL; Remme WJ; Holwerda KJ; Kruijssen DA
Eur Heart J; 1996 Mar; 17(3):414-20. PubMed ID: 8737216
[TBL] [Abstract][Full Text] [Related]
42. Ketamine as an Alternative Anesthetic for Augmenting Seizure Durations During Electroconvulsive Therapy: A Retrospective Observational Study.
Mutoh S; Kinoshita M; Maeda Y; Tanaka K
J ECT; 2024 Jun; 40(2):134-139. PubMed ID: 38109337
[TBL] [Abstract][Full Text] [Related]
43. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population.
Herrera CR; Lewin A; Fiddes R; Friedman J; Linn W; Baker T; Balanoff D; Beach CL
Pharmacotherapy; 1997; 17(6):1254-9. PubMed ID: 9399608
[TBL] [Abstract][Full Text] [Related]
44. Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression.
Kayser S; Bewernick BH; Hurlemann R; Soehle M; Schlaepfer TE
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1541-50. PubMed ID: 23820052
[TBL] [Abstract][Full Text] [Related]
45. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension.
Pool PE; Seagren SC; Salel AF
Am J Cardiol; 1985 Dec; 56(16):86H-91H. PubMed ID: 3907322
[TBL] [Abstract][Full Text] [Related]
46. Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris.
Wallace WA; Wellington KL; Murphy GW; Liang CS
Am J Cardiol; 1989 Feb; 63(7):414-8. PubMed ID: 2492741
[TBL] [Abstract][Full Text] [Related]
47. Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response.
Minelli A; Abate M; Zampieri E; Gainelli G; Trabucchi L; Segala M; Sartori R; Gennarelli M; Conca A; Bortolomasi M
J ECT; 2016 Jun; 32(2):88-92. PubMed ID: 26397151
[TBL] [Abstract][Full Text] [Related]
48. Comparison of two esmolol bolus doses on the haemodynamic response and seizure duration during electroconvulsive therapy.
Kovac AL; Goto H; Pardo MP; Arakawa K
Can J Anaesth; 1991 Mar; 38(2):204-9. PubMed ID: 1673645
[TBL] [Abstract][Full Text] [Related]
49. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy.
Avramov MN; Husain MM; White PF
Anesth Analg; 1995 Sep; 81(3):596-602. PubMed ID: 7653829
[TBL] [Abstract][Full Text] [Related]
50. Ketofol (mixture of ketamine and propofol) administration in electroconvulsive therapy.
Erdogan Kayhan G; Yucel A; Colak YZ; Ozgul U; Yologlu S; Karlıdag R; Ersoy MO
Anaesth Intensive Care; 2012 Mar; 40(2):305-10. PubMed ID: 22417026
[TBL] [Abstract][Full Text] [Related]
51. Caffeine Sodium Benzoate for Electroconvulsive Therapy Augmentation.
Bozymski KM; Potter TG; Venkatachalam V; Pandurangi AK; Crouse EL
J ECT; 2018 Dec; 34(4):233-239. PubMed ID: 29768288
[TBL] [Abstract][Full Text] [Related]
52. Effects of the concurrent use of a reduced dose of propofol with divided supplemental remifentanil and moderate hyperventilation on duration and morphology of electroconvulsive therapy-induced electroencephalographic seizure activity: A randomized controlled trial.
Nishikawa K; Yamakage M
J Clin Anesth; 2017 Feb; 37():63-68. PubMed ID: 28235531
[TBL] [Abstract][Full Text] [Related]
53. [Anesthesia for electroconvulsive therapy -- comparison of propofol with sevoflurane].
Matsubara T; Yamamoto H; Hikawa Y
Masui; 2012 Jul; 61(7):733-7. PubMed ID: 22860302
[TBL] [Abstract][Full Text] [Related]
54. Seizure expression during electroconvulsive therapy: relationships with clinical outcome and cognitive side effects.
Perera TD; Luber B; Nobler MS; Prudic J; Anderson C; Sackeim HA
Neuropsychopharmacology; 2004 Apr; 29(4):813-25. PubMed ID: 14735129
[TBL] [Abstract][Full Text] [Related]
55. Beta-blocking agents during electroconvulsive therapy: a review.
Boere E; Birkenhäger TK; Groenland TH; van den Broek WW
Br J Anaesth; 2014 Jul; 113(1):43-51. PubMed ID: 24942714
[TBL] [Abstract][Full Text] [Related]
56. The effects of etomidate on seizure duration and electrical stimulus dose in seizure-resistant patients during electroconvulsive therapy.
Khalid N; Atkins M; Kirov G
J ECT; 2006 Sep; 22(3):184-8. PubMed ID: 16957534
[TBL] [Abstract][Full Text] [Related]
57. Exploring Brain and Heart Interactions during Electroconvulsive Therapy with Point-of-Care Ultrasound.
Chang MG; Barbour TA; Bittner EA
Med Sci (Basel); 2024 Mar; 12(2):. PubMed ID: 38525771
[TBL] [Abstract][Full Text] [Related]
58. Duration of Pupillary Unresponsiveness to Light: A Physiological Adjunct to Electroencephalography and Motor Seizure Duration Monitoring During Electroconvulsive Therapy.
Venkataramaiah S; Umamaheswara Rao GS; Kamath S; Jadhav T; Kumar CN; Arumugham SS; Reddy M; Philip M; Thirthalli J
J ECT; 2018 Dec; 34(4):e61-e64. PubMed ID: 29613942
[TBL] [Abstract][Full Text] [Related]
59. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.
Howie MB; Hiestand DC; Zvara DA; Kim PY; McSweeney TD; Coffman JA
Anesth Analg; 1992 Nov; 75(5):805-10. PubMed ID: 1358003
[TBL] [Abstract][Full Text] [Related]
60. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy.
Sackeim HA; Devanand DP; Prudic J
Psychiatr Clin North Am; 1991 Dec; 14(4):803-43. PubMed ID: 1771150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
